Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20062887 | 0.81 | HTT (0.56) | CYP2A6CYP2E1CYP3A4HTTELANE | |
| SCHEMBL20062891 | 0.78 | HTT (0.50) | CYP2A6CYP2E1CYP3A4HTTELANE | |
| SCHEMBL20062895 | 0.78 | ALDH1A1 (0.44) | CYP2A6CYP2E1CYP3A4HTTELANE | |
| SCHEMBL20062900 | 0.78 | CYP11B2 (0.46) | CYP2A6CYP2E1CYP3A4HTTELANE | |
| SCHEMBL20681860 | 0.77 | CYP2A6 (0.45) | CYP2A6CYP2E1CYP3A4HTTMAPT | |
| SCHEMBL20062905 | 0.77 | BCHE (0.42) | ARALDH1A1L3MBTL1 | |
| SCHEMBL17383518 | 0.77 | NPC1 (0.45) | ELANEGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL4122353 | 0.76 | HTT (0.70) | CYP2A6CYP2E1CYP3A4HTTELANE | |
| SCHEMBL20062904 | 0.74 | TDP1 (0.47) | CYP2A6CYP2E1CYP3A4HTTELANE | |
| SCHEMBL18905756 | 0.73 | NPC1 (0.42) | HTTELANEGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10541260-B2 | Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus | CANON KABUSHIKI KAISHA (JP) | 2020-01-21 | — | — | US | disclosed |
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | CANON KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | BRD1, DRD1, NR2E3 | CYP2A6 1062/4885CYP2E1 878/4885CYP3A4 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.